Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Read more about Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
Travere Therapeutics to Report Third Quarter 2023 Financial Results Read more about Travere Therapeutics to Report Third Quarter 2023 Financial Results
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 Read more about Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023) Read more about Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan Read more about Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)